Saturday 7 November 2026
Export LYEL’s income statement to Excel — free account
Lyell Immunopharma, Inc.
LYEL Healthcare Biotechnology
Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024.
- Revenue
- −80.0%
- EPS
- +12.7%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
14.82
0.18
−1.20%
Follow LYEL
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 2 | 2 |
+8 more TTM periods Free account |
| (97.79%) | (93.28%) | (80.76%) | (86.98%) | ||
| (74.85%) | (71.34%) | (63.15%) | (66.06%) | ||
ROIC |
(1,070.83%) | (539.53%) | (815.53%) | (17,146.38%) | |
Return on Tangible Assets |
(151.45%) | (121.69%) | (93.66%) | (111.43%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(5.70) | (7.48) | (8.01) | (11.22) | |
Free Cash Flow |
(139.25) | (174.87) | (175.33) | (191.71) | |
Capital Expenditures |
— | (41.61) | (41.53) | (41.69) | |
| Other line items | |||||
Cash ROIC |
(37.65%) | (39.93%) | (33.23%) | (38.70%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 579,625.93% | 489,780.65% | 440,763.89% | |
Selling, General and Administrative Expense of Revenue |
260,293.33% | 149,755.56% | 131,109.68% | 125,375.00% | |
Share Based Compensation of Revenue |
259,400.00% | 146,770.37% | 129,354.84% | 116,191.67% | |
Operating CF/Net income |
0.55 | 0.54 | 0.54 | 0.55 | |
Depreciation/Fixed assets |
0.19 | 0.19 | 0.19 | 0.19 | |
Capex/Depreciation |
0.00 | (7.25) | (6.58) | (6.34) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.70) | (5.70) | (6.12) | (8.78) | |
Capex per Share |
0.00 | (1.78) | (1.90) | (2.44) | |
Capex to Sales |
0.00 | 1,541.26 | 1,339.71 | 1,158.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026